Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery

Archive ouverte

Hausenloy, D. J. | Barrabes, J. A. | Botker, H. E. | Davidson, S. M. | Di Lisa, F. | Downey, J. | Engstrom, T. | Ferdinandy, P. | Carbrera-Fuentes, H. A. | Heusch, G. | Ibanez, B. | Iliodromitis, E. K. | Inserte, J. | Jennings, R. | Kalia, N. | Kharbanda, R. | Lecour, S. | Marber, M. | Miura, T. | Ovize, Michel | Perez-Pinzon, M. A. | Piper, H. M. | Przyklenk, K. | Schmidt, M. R. | Redington, A. | Ruiz-Meana, M. | Vilahur, G. | Vinten-Johansen, J. | Yellon, D. M. | Garcia-Dorado, D.

Edité par CCSD ; Springer Verlag -

International audience. To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research.

Consulter en ligne

Suggestions

Du même auteur

Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart

Archive ouverte | Hausenloy, D. J. | CCSD

International audience. Ischaemic heart disease and the heart failure that often results, remain the leading causes of death and disability in Europe and worldwide. As such, in order to prevent heart failure and imp...

Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply

Archive ouverte | Hausenloy, D. J. | CCSD

International audience

ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies

Archive ouverte | Lecour, S. | CCSD

International audience. Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of a...

Chargement des enrichissements...